In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.
Men and women aged 18 years and older.
Patients with type 2 diabetes.
Written informed consent of the patient to participate in the study.
No conditions that require emergency medical aid.
Known hypersensitivity to luseogliflozin or other components of Lusefi®.
Type 1 diabetes.
Decompensated type 2 diabetes.
Pregnancy, breastfeeding, or planned pregnancy during the study and at least two months after the study.
patients with type 2 diabetes in real-world clinical practice Every investigator is expected to include about 4 patients that meet the inclusion/exclusion criteria. Inclusion period will last up to 6 months.
Other
Cross-sectional
Not listed
Hypoglycemic effectiveness of luseogliflozin in patients with type 2 diabetes (glycated hemoglobin)
Change in glycated hemoglobin (HbA1c) level by the end of the observation period (Visit 3) compared to baseline
Hypoglycemic effectiveness of luseogliflozin in patients with type 2 diabetes (plasma glucose)
Change in fasting plasma glucose (FPG) level at Visit 3 compared to baseline.
Effectiveness of luseogliflozin on Body weight
Change in Body weight (BW) at Visit 3 compared to baseline.
Effectiveness of luseogliflozin on systolic blood pressure (SBP)
Change in systolic blood pressure (SBP) at Visit 3 compared to baseline
Effectiveness of luseogliflozin on diastolic blood pressure ( DBP)
Change in diastolic blood pressure (DBP) at Visit 3 compared to baseline.
Click on the lead sponsor to view all of their trials.
